Medpace Holdings, Inc. with ticker code (MEDP) now have 4 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between 273 and 260 with the average target price sitting at $267.00. Given that the stocks previous close was at $260.39 this would imply there is now a potential upside of 2.5%. The 50 day MA is $234.51 while the 200 day moving average is $213.30. The total market capitalization for the company now stands at 8.03B. The stock price for the company is currently 263.16 USD
The potential market cap would be $8,229,886,873 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 32.05, revenue per share of 54.09 and a 14.64% return on assets.
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focuses on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. It also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
